There are no effective treatments for rhabdoid tumors -- aggressive childhood cancers that usually strike children under three years old and affect the brain or kidneys. The disease is extremely rare -- fewer than 10 cases are diagnosed each year in the U.S. -- but is particularly difficult to treat and almost always fatal.
Now scientists at Albert Einstein College of Medicine of Yeshiva University have identified a target for potential therapies for these tumors: a gene called Aurora A that is vital for tumor growth. The research team was led by Ganjam Kalpana, Ph.D., professor of genetics and of microbiology & immunology, the Mark Trauner Faculty Scholar in Neuro-oncology at Einstein. Their findings appear in the April 26 online issue of Cancer Research.
The Aurora A gene is known to be expressed at higher-than-normal levels in many cancers, and its expression is associated with poor prognosis. Scientists have also known that mutations in a tumor suppressor gene called INI1/hSNF5 can lead to rhabdoid tumors. In this study, the Kalpana team found that, in rhabdoid tumors, loss of the tumor suppressor gene INI1/hSNF5 leads to changes in Aurora A's expression that are crucial for tumor growth.
In experiments involving rhabdoid tumors and tumor cell lines, the Einstein scientists showed for the first time that Aurora A is highly expressed in both human and mouse rhabdoid tumors, that the loss of the INI1/hSNF5 tumor suppressor gene from rhabdoid tumor cells leads to the "de-repression" of Aurora A, and that knocking down Aurora A's expression in rhabdoid tumor cells potently inhibits the growth of those cells.
"Our findings indicate that targeting Aurora A could be an effective strategy for halting rhabdoid tumor growth," said Dr. Kalpana. She notes that many Aurora A inhibitors are now being tested against several types of cancers, includingmelanoma and non-Hodgkin's lymphoma, and other researchers have now expressed interest in using Aurora A inhibitors in trials for children with rhabdoid brain tumors.
Seung Jae Lee, Ph.D., a postdoctoral fellow in the Kalpana laboratory, is the first author of the paper and played a major role in the study. He was helped by Velasco Cimica, Ph.D., and Nandini Ramachandra, M.S., both at Einstein. David Zagzag, M.D., at New York University provided clinical samples and performed immunohistochemistry. The paper is titled "Aurora A is a Repressed Effector Target of the Chromatin Remodeling Protein INI1/hSNF5 Required for Rhabdoid Tumor Cell Survival." The research was funded with grants from the American Cancer Society, Children's Tumor Foundation, the Department of Defense, Albert Einstein Cancer Center, and the Feinberg Foundation.
Materials provided by Albert Einstein College of Medicine. Note: Content may be edited for style and length.
Cite This Page: